Cediranib
Recurrent Disease
National Cancer Institute (NCI)Small moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Recurrent Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Benadryl Fred Hutchinson Cancer Center | Phase 2 | B |
Monomethyl Fumarate Fred Hutchinson Cancer Center | Phase 2 | B |
PREDNISONE TABLETS Children's Oncology Group | Phase 1 | CCC |
Cyclophosphamide National Cancer Institute (NCI) | Phase 1 | CC |
Azacitidine National Cancer Institute (NCI) | Phase 1 | CC |
DEXAMETHASONE National Cancer Institute (NCI) | Phase 1 | CC |
Same molecule, other indications
Cediranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →